DOP2003000614A - Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole - Google Patents

Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole

Info

Publication number
DOP2003000614A
DOP2003000614A DO2003000614A DO2003000614A DOP2003000614A DO P2003000614 A DOP2003000614 A DO P2003000614A DO 2003000614 A DO2003000614 A DO 2003000614A DO 2003000614 A DO2003000614 A DO 2003000614A DO P2003000614 A DOP2003000614 A DO P2003000614A
Authority
DO
Dominican Republic
Prior art keywords
bencimidazol
rented
derivatives
mek inhibitors
compounds
Prior art date
Application number
DO2003000614A
Other languages
English (en)
Inventor
Eli M Walllace
Joe P Lyssikatos
Allison L Marlow
T Brian Hurley
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of DOP2003000614A publication Critical patent/DOP2003000614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se revelan compuestos de la fórmula y sales farmacéuticamente aceptadas y prodrogas de ellos, en donde W, t, R11 Y R12 son según fueron definidos en la memoria descriptiva. Estos compuestos son inhibidores de MEK y son útiles en el tratamiento de enfermedades hiperproliferativas, tales como cáncer e inflamación, en mamíferos. También se revela un método para usar estos compuestos para el tratamiento de enfermedades hiperproliferativas y composiciones farmacéuticas que contienen tales compuestos.
DO2003000614A 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole DOP2003000614A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36416402P 2002-03-13 2002-03-13

Publications (1)

Publication Number Publication Date
DOP2003000614A true DOP2003000614A (es) 2009-09-30

Family

ID=28041882

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000614A DOP2003000614A (es) 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole

Country Status (18)

Country Link
US (2) US20030216460A1 (es)
EP (1) EP1482944A4 (es)
JP (1) JP2005526076A (es)
KR (1) KR20040098013A (es)
CN (1) CN1652792A (es)
AR (1) AR038972A1 (es)
AU (1) AU2003220202A1 (es)
CA (1) CA2478534A1 (es)
CO (1) CO5611145A2 (es)
DO (1) DOP2003000614A (es)
IL (1) IL163996A0 (es)
MX (1) MXPA04008894A (es)
PA (1) PA8569201A1 (es)
PL (1) PL378635A1 (es)
RU (1) RU2300528C2 (es)
TW (1) TW200406203A (es)
UA (1) UA76837C2 (es)
WO (1) WO2003077855A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343377B (en) * 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
BRPI0412851A (pt) 2003-07-24 2006-10-03 Warner Lambert Co benzamidazóis de n-metila-substituìdos
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
AR051248A1 (es) 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
ATE443063T1 (de) * 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
CN102898364A (zh) 2005-05-18 2013-01-30 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CN101248060B (zh) 2005-06-23 2014-09-10 阵列生物制药公司 用于制备苯并咪唑化合物的方法
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CN103524392B (zh) * 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
EP1966155A1 (en) * 2005-12-21 2008-09-10 AstraZeneca AB Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006032A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101511842B (zh) 2006-07-06 2012-10-31 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
CN101583616B (zh) * 2006-08-21 2012-05-30 健泰科生物技术公司 氮杂苯并噻吩基化合物及使用方法
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008157179A2 (en) 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
SI2173723T1 (sl) 2007-07-05 2011-12-30 Array Biopharma Inc Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2704125A1 (en) 2007-12-19 2009-07-09 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
PE20131210A1 (es) * 2007-12-19 2013-10-31 Genentech Inc Derivados de 5-anilinoimidazopiridina como inhibidores de mek
ES2387707T3 (es) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizinas y procedimientos de uso
JP5346345B2 (ja) 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
JP5615274B2 (ja) * 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
SI2307376T1 (sl) 2008-08-04 2016-02-29 Merck Patent Gmbh Nove spojine fenilamino izonikotinamida
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
ES2616238T3 (es) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Derivados de bencimidazol como inhibidores de PI3 quinasa
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
KR20140022053A (ko) 2011-04-01 2014-02-21 제넨테크, 인크. Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
CA2836364C (en) 2011-05-25 2021-01-26 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
KR20150013332A (ko) 2012-05-31 2015-02-04 바이엘 파마 악티엔게젤샤프트 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커
HRP20180670T1 (hr) 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
DK2976106T3 (da) 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
CN111646946A (zh) 2017-11-14 2020-09-11 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022251193A1 (en) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Combination therapies
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
AU2201500A (en) * 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
AU6068600A (en) * 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors

Also Published As

Publication number Publication date
UA76837C2 (uk) 2006-09-15
IL163996A0 (en) 2005-12-18
MXPA04008894A (es) 2005-06-20
EP1482944A2 (en) 2004-12-08
US20060106225A1 (en) 2006-05-18
CO5611145A2 (es) 2006-02-28
EP1482944A4 (en) 2006-04-19
KR20040098013A (ko) 2004-11-18
AR038972A1 (es) 2005-02-02
JP2005526076A (ja) 2005-09-02
CA2478534A1 (en) 2003-09-25
WO2003077855A2 (en) 2003-09-25
TW200406203A (en) 2004-05-01
AU2003220202A1 (en) 2003-09-29
PA8569201A1 (es) 2004-05-21
CN1652792A (zh) 2005-08-10
PL378635A1 (pl) 2006-05-15
US20030216460A1 (en) 2003-11-20
RU2300528C2 (ru) 2007-06-10
WO2003077855A3 (en) 2004-03-04
RU2004127925A (ru) 2005-05-27

Similar Documents

Publication Publication Date Title
DOP2003000613A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
PA8569201A1 (es) "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
EA200700902A1 (ru) 3-ариламинопиридиновые производные
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
ECSP11011151A (es) Compuestos purina
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2011000777A1 (es) Compuestos derivados de imidazopiridazina, inhibidor de proteína quinasa; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, psoriasis, artritis reumatoide, angiogenesis, entre otras.
UY28572A1 (es) Compuestos novedosos
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
UY31457A1 (es) Derivados acidos de cicloalquilamino
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
DOP2010000175A (es) Inhibidores de cinesina como productos terapeuticos para el cancer
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
CU20120085A7 (es) Derivados de sulfamidas heterocíclicas
GT200800296A (es) Derivados de ácido fenilacético